The Prurigo Nodularis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Prurigo Nodularis: An Overview
Prurigo nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. The main symptom of Prurigo Nodularis is the formation of hard, very itchy lumps (nodules) on the skin. The nodules can range in size from very small to about half an inch in diameter.
Prurigo Nodularis Market Key Facts
-
The total prevalent population of Prurigo Nodularis in the seven major markets was found to be 689,760 in 2017.
-
Among the European countries, Germany had the highest prevalent population of Prurigo Nodularis with 103,004 cases, followed by France with 57,996 cases in 2017. Besides, Spain had the lowest prevalent population with 44,273 cases in 2017.
-
Japan accounted for the second-highest prevalent population of Prurigo Nodularis among the 7MM countries, with over 110,681 cases in 2017 that will increase by the end of 2028.
-
As per DelveInsight’s analysis, it has been observed that most of the patients with Atopic PN account for 75% of the total diagnosed Prurigo Nodularis cases, followed by Nonatopic PN (25%) in the United States.
The market size of Prurigo Nodularis is expected to increase during the forecast period owing to the rise in the prevalent population of Prurigo Nodularis in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Prurigo Nodularis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Prurigo Nodularis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/prurigo-nodularis-market
Prurigo Nodularis Epidemiology
The epidemiology section covers insights about the historical and current Prurigo Nodularis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Prurigo Nodularis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched in the market during the study period. The analysis covers Prurigo Nodularis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Prurigo Nodularis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Prurigo Nodularis Therapeutics Analysis
The Prurigo Nodularis (PN) therapeutics market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies.
Some of the key companies in the Prurigo Nodularis market include:
-
Menlo Therapeutics
-
Trevi Therapeutics
-
Kiniksa Pharmaceuticals
-
Galderma
-
Sanofi
And others.
Prurigo Nodularis Therapies Covered in the Report:
-
Serlopitant
-
Nalbuphine ER
-
KPL-716
-
Nemolizumab
-
Dupilumab
And many others.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/prurigo-nodularis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Prurigo Nodularis Competitive Intelligence Analysis
4. Prurigo Nodularis Market Overview at a Glance
5. Prurigo Nodularis Disease Background and Overview
6. Prurigo Nodularis Patient Journey
7. Prurigo Nodularis Epidemiology and Patient Population
8. Prurigo Nodularis Treatment Algorithm, Current Treatment, and Medical Practices
9. Prurigo Nodularis Unmet Needs
10. Key Endpoints of Prurigo Nodularis Treatment
11. Prurigo Nodularis Marketed Products
12. Prurigo Nodularis Emerging Therapies
13. Prurigo Nodularis Seven Major Market Analysis
14. Attribute Analysis
15. Prurigo Nodularis Market Outlook (7 major markets)
16. Prurigo Nodularis Access and Reimbursement Overview
17. KOL Views on the Prurigo Nodularis Market.
18. Prurigo Nodularis Market Drivers
19. Prurigo Nodularis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/prurigo-nodularis-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
